Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
October 2019
-
Media ReleaseAveXis presents updated STRONG data at WMSOlder patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
-
Women in Science: Lauren Abrey
Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.
-
Key ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumPhase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
-
Media ReleaseNovartis and Microsoft announce collaboration to transform medicine with artificial intelligenceMultiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
September 2019
-
Word on the Street: What is cell and gene therapy?
We leave the lab to find out what people know about cell and gene therapy.
-
Media ReleaseNovartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthmaOnce-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint[1] PALLADIUM is part of Phase III PLATINUM clinical development program,…
-
Media ReleaseNovartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthmaOnce-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint[1],[2] IRIDIUM is largest study in Phase III PLATINUM clinical…
-
Key ReleaseNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patientsIn MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
-
Featured NewsEuropean Patient Innovation Summit recommends increasing the impact of digital technologies
European Patient Innovation Summit publishes a position paper on Digital Health from a Patient Perspective with recommendations on digital health.
-
Seeing through knees in quest to alleviate osteoarthritis
Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.
-
StatementAveXis data integrity - updates
Form 483 posting by US Food and Drug Administration (FDA) – Novartis statement
-
Media ReleaseAveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gainUpdated results from global…
Pagination
- ‹ Previous page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- …
- 151
- › Next page